Company news

Annexon, Inc. news in 2025

Annexon, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

December 16, 2025

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

November 14, 2025

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

November 10, 2025

Annexon Biosciences to Participate in Upcoming September Investor Conferences

August 27, 2025

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

August 14, 2025

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

August 7, 2025

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

July 24, 2025

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

June 18, 2025

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 29, 2025

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 19, 2025

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 12, 2025

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 9, 2025

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

May 7, 2025

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

April 8, 2025

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

April 3, 2025

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

March 3, 2025

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

February 26, 2025

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

February 12, 2025

Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year

January 12, 2025

Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones

January 9, 2025

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Decks in 2025